Furthermore, the response to immunotherapy targeting PD-1 or cytotoxic T lymphocyte-associated antigen (CTLA)-4 varies with gut microbiota composition in both tumour-bearing mice and patients [24,25,26]. The gene discussed is CTLA4; the disease is neoplasm.